Consolidated Alcon Eye Division Has Key Role In Maintaining Novartis’ Growth
Executive Summary
Like many other big pharma companies, Novartis AG faces an imminent patent cliff, with blood pressure blockbuster Diovan (valsartan), among other products, due to lose patent protection soon.
You may also be interested in...
NicOx Kicks Off Specialty Ophthalmics Transformation With Altacor Buy
France's NicOx, aiming to transform into a specialty ophthalmology company after several late-stage disappointments, announced plans to acquire VC-backed U.K startup Altacor.
Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal
Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.
Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter
Novartis lifted by strong sales of recently launched products in the second quarter, and by strong growth in its Alcon, generics and consumer health divisions.